SCHEMBL23988415

SCHEMBL23988415

COc1ccnc(CS(=O)(=O)c2nc3ccccc3[nH]2)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
TP53 P04637 1/20 0.51
CYP2C9 P11712 5/20 0.48
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
WDR5 P61964 3/20 0.41
KMT2A Q03164 3/20 0.41
DDAH1 O94760 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
ADRA1A P35348 2/20 0.41
FASN P49327 2/20 0.41
ABCG2 Q9UNQ0 2/20 0.41
KDM4E B2RXH2 2/20 0.41
SARM1 Q6SZW1 2/20 0.41
ENGASE Q8NFI3 2/20 0.41
HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988420 0.89 CYP2C9 (0.51) ALDH1A1TP53CYP2C9L3MBTL1NPC1
SCHEMBL23988520 0.86 CYP2C9 (0.56) ALDH1A1TP53CYP2C9KMT2ADDAH1
SCHEMBL23988416 0.83 CYP2C9 (0.42) ALDH1A1TP53CYP2C9RAB9ADDAH1
SCHEMBL538298 0.81 ATP4A (0.56) ALDH1A1CYP2C9WDR5KMT2ADDAH1
SCHEMBL15475057 0.81 ATP4A (0.66) ALDH1A1CYP2C9WDR5KMT2ADDAH1
SCHEMBL23988474 0.81 RUNX1 (0.51) ALDH1A1CYP2C9DDAH1LMNAMAPT
SCHEMBL30102856 0.81 ATP4A (0.56) ALDH1A1CYP2C9WDR5KMT2ADDAH1
SCHEMBL1307379 0.80 KMT2A (0.63) ALDH1A1TP53CYP2C9L3MBTL1NPC1
SCHEMBL30905609 0.80 KMT2A (0.63) ALDH1A1TP53CYP2C9L3MBTL1NPC1
SCHEMBL6600434 0.79 KMT2A (0.62) ALDH1A1TP53CYP2C9L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202796-A1 CXCL10 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-06-30 US disclosed
US-20210338650-A1 CXCL10 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202796-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 ALDH1A1 3507/4885TP53 1556/4885CYP2C9 4152/4885
US-20210338650-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 ALDH1A1 3507/4885TP53 1556/4885CYP2C9 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.